Q1 2023 Results
Company overview
Innovation: Pipeline overview
Financial review
Financial performance
Cardiovascular
Immunology
Ophthalmology
libvatrep - TRPV1 antagonist
NCT04630158 SAHARA (CSAF312B12201)
Chronic ocular surface pain
Indication
Phase
Phase 2
Patients
150
Primary
Outcome
Measures
Arms
Intervention
Change in mean pain severity Visual Analog Scale
Conclusions
Neuroscience
Global Health
Target
Patients
Placebo Comparator: SAF312 Placebo. Randomized to a 1:1:1 topical eye
drops, twice daily
Experimental: SAF312 dose 1. Randomized to a 1:1:1 topical eye drops,
twice daily
Experimental: SAF312 dose 2. Randomized to a 1:1:1 topical eye drops,
twice daily
Subjects with CICP persisting at least for 4 months after refractive surgery and
chronicity confirmed during the observational period.
Readout
Milestone(s)
2023
Publication
2023
85 Investor Relations | Q1 2023 Results
Appendix
References
Innovation: Clinical trials
Abbreviations
Oncology
Other
Biosimilars
1 NOVARTIS | Reimagining MedicineView entire presentation